ID

45994

Description

Principal Investigator: Arul Chinnaiyan, University of Michigan, MI, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000915 Most prostate cancer deaths are caused by metastatic, castration resistant disease (mCRPC). To develop a precision medicine framework for mCRPC, we established a multi-institutional, international clinical sequencing infrastructure to enroll and carry out prospective whole exome and transcriptome sequencing of tumors from a cohort of mCRPC patients. We obtained high quality DNA and RNA sequence data from 150 bone or soft tissue biopsies. Central pathology revealed high-grade adenocarcinoma with only four cases (3.6%) showing neuroendocrine differentiation. Aberrations of AR, ETS genes, TP53 and PTEN were frequent (40-60% of cases), with TP53 and AR alterations being the most enriched in mCRPC compared to primary prostate cancer. We identified novel genomic alterations in PIK3CA/B (fusions and mutations); R-spondin, BRAF and RAF1 (fusions); APC (inactivating mutations); delta-catenin (missense mutations); and ZBTB16/PLZF (homozygous deletions). Aberrations of BRCA2, BRCA1 and ATM were observed at substantially higher frequencies (19.3% overall) than seen in primary prostate cancers, with 56% of these being exclusively somatic. Putative driver gene alterations were identified in nearly all patients, and over half also harbored driver gene fusions, homozygous deletions and/or amplifications. Moreover, 89% of patients harbored a clinically actionable aberration including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. Overall, integrative clinical sequencing analysis can be safely and efficiently performed in mCRPC, yields findings that may be actionable for enrolling patients in clinical trials of targeted therapies, and may inform the basis of individual clinical responses.

Lien

dbGaP study=phs000915

Mots-clés

  1. 14/04/2024 14/04/2024 - Madita Rudolph
Détendeur de droits

Arul Chinnaiyan, University of Michigan, MI, USA

Téléchargé le

14 avril 2024

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

dbGaP phs000915 Integrative Clinical Sequencing Analysis of Metastatic Castration Resistant Prostate Cancer Reveals a High Frequency of Clinical Actionability

Subject ID and main disease for which the participant has been asked to donate a sample for study of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.

pht004946
Description

pht004946

Alias
UMLS CUI [1,1]
C3846158
Unique participant identifier
Description

SUBJECT_ID

Type de données

string

Alias
UMLS CUI [1,1]
C2348585
The main disease(s) for which the participant has been asked to donate a sample for study [Metastatic Prostate Cancer]
Description

Primary Disease

Type de données

string

Alias
UMLS CUI [1,1]
C0277554
UMLS CUI [1,2]
C0080231

Similar models

Subject ID and main disease for which the participant has been asked to donate a sample for study of participants with prostate cancer and involved in the "Stand Up To Cancer East Coast Prostate Cancer Research Group" project.

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
pht004946
C3846158 (UMLS CUI [1,1])
SUBJECT_ID
Item
Unique participant identifier
string
C2348585 (UMLS CUI [1,1])
Primary Disease
Item
The main disease(s) for which the participant has been asked to donate a sample for study [Metastatic Prostate Cancer]
string
C0277554 (UMLS CUI [1,1])
C0080231 (UMLS CUI [1,2])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial